Does Rallies show Form 4 insider transactions for FOLD?

Yes. Rallies tracks FOLD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is FOLD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FOLD. It does not provide personalized investment advice.

FOLD (Amicus Therapeutics, Inc) Stock Analysis - Insider Trades

Amicus Therapeutics, Inc (FOLD) is a publicly traded Healthcare sector company. As of May 20, 2026, FOLD trades at $14.49 with a market cap of $4.55B and a P/E ratio of -161.00. FOLD moved +0.00% today. Year to date, FOLD is +47.11%; over the trailing twelve months it is +101.25%. Its 52-week range spans $5.51 to $14.50. Analyst consensus is buy with an average price target of $14.50. Rallies surfaces FOLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading FOLD stock inside the company?

Recent FOLD insider activity includes Campbell Bradley L sold 22.50K, Campbell Bradley L sold 75.00K, Clark David Michael sold 25.64K, Campbell Bradley L sold 77.93K, and Clark David Michael sold 25.64K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

FOLD Key Metrics

Key financial metrics for FOLD
Metric	Value
Price	$14.49
Market Cap	$4.55B
P/E Ratio	-161.00
EPS	$-0.09
Dividend Yield	0.00%
52-Week High	$14.50
52-Week Low	$5.51
Volume	5.29M
Avg Volume	0
Revenue (TTM)	$634.21M
Net Income	$-27.11M
Gross Margin	88.50%

Recent FOLD Insider Trades

Campbell Bradley L sold 22.50K (~$322.84K) on Mar 2, 2026.
Campbell Bradley L sold 75.00K (~$1.07M) on Jan 20, 2026.
Clark David Michael sold 25.64K (~$363.38K) on Dec 19, 2025.
Campbell Bradley L sold 77.93K (~$846.01K) on Dec 15, 2025.
Clark David Michael sold 25.64K (~$282.07K) on Dec 15, 2025.

Latest FOLD News

BioMarin Completes $4.8bn Amicus Acquisition Adding Two Rare Disease Drugs — Apr 28, 2026
BioMarin Wins FDA Approval for Palynziq in Patients Aged 12+ With PKU — Mar 2, 2026
Amicus Q4 Revenue Beats on Galafold; BioMarin $4.8B Deal — Feb 23, 2026
Amicus Therapeutics' 2025 Revenue Up 17% to $634.2M, Q2 2026 BioMarin Deal — Feb 20, 2026
Amicus Therapeutics Sees 41.7% Surprise, Q4 Sales Estimated at $179.9M — Feb 16, 2026

FOLD Analyst Consensus

24 analysts cover FOLD: 0 strong buy, 16 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.50.

Common questions about FOLD

Who is trading FOLD stock inside the company?: Recent FOLD insider activity includes Campbell Bradley L sold 22.50K, Campbell Bradley L sold 75.00K, Clark David Michael sold 25.64K, Campbell Bradley L sold 77.93K, and Clark David Michael sold 25.64K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for FOLD?: Yes. Rallies tracks FOLD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is FOLD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FOLD. It does not provide personalized investment advice.